Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Arvinas, Inc. (ARVN)
USD8.18
-0.09 (-1.15%)
US NASDAQ Healthcare Biotechnology
Address
5 Science Park 6511
New Haven, CT, US
New Haven, CT, US
CEO
Randy Teel
Website
arvinas.com
IPO
2018-09-27
CIK 1655759 ISIN US04335A1051
Description
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD8.18
-0.09 (-1.15%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
885.8K
Beta
1.75
Float Shares
55.41M
Free Float %
86.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.93% | -5.43% | -9.55% | -17.85% | -5.43% | -19.31% | +52.15% | -59.79% | -85.01% | -40.37% | -40.37% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (26 ratings, all time)
Buy
Price Targets & DCF
Current price
8.18
Low
10.00
+22.3%
Consensus
13.00
+59.0%
Median
11.00
+34.6%
High
18.00
+120.2%
Ratings Trend (MoM)
53% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 8 | 0 |
| Hold | 8 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 2 |
10.50
+28.4%
|
| Last Year | 10 |
13.90
+70.0%
|
| All Time | 34 |
48.74
+496.2%
|
Quality scores
Altman Z-Score
-2.31
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-0.3% Q1'26: -91.7% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+53.8% ★ Q1'26: -178.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-118.5% Q1'26: -451.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-30.7% Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-9.7% ★ Q1'26: -12.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.11× Q1'26: -0.03× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 13 Rev. Ana. 12 EPS Ana. |
Dec 2027 11 Rev. Ana. 11 EPS Ana. |
Dec 2028 10 Rev. Ana. 8 EPS Ana. |
Dec 2029 5 Rev. Ana. 6 EPS Ana. |
Dec 2030 5 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
14.32M
est: 14.26M (+0.5%)
|
42.98M
est: 43.39M (-0.9%)
|
25.90M
est: 26.24M (-1.3%)
|
53.60M
est: 74.13M (-27.7%)
|
131.40M
est: 120.80M (+8.8%)
|
78.50M
est: 93.30M (-15.9%)
|
263.40M
est: 264.73M (-0.5%)
|
262.60M
est: 289.43M (-9.3%)
|
94.16M
44.13M – 154.46M
-67.5% YoY
|
81.25M
32.75M – 125.66M
-13.7% YoY
|
112.71M
41.02M – 204.57M
+38.7% YoY
|
176.15M
64.11M – 319.71M
+56.3% YoY
|
246.59M
89.75M – 447.55M
+40.0% YoY
|
| EBITDA |
-40.72M
est: -14.04M (-189.9%)
|
-67.95M
est: -42.73M (-59.0%)
|
-117.60M
est: -25.85M (-355.0%)
|
-182.40M
est: -209.59M (+13.0%)
|
-255.00M
est: -208.14M (-22.5%)
|
-394.80M
est: -78.59M (-402.4%)
|
-243.60M
est: -222.99M (-9.2%)
|
-75.30M
est: -243.79M (+69.1%)
|
-79.31M
-130.10M – -37.17M
+67.5% YoY
|
-68.43M
-105.85M – -27.59M
+13.7% YoY
|
-94.94M
-172.31M – -34.55M
-38.7% YoY
|
-148.38M
-269.29M – -54.00M
-56.3% YoY
|
-207.71M
-376.97M – -75.60M
-40.0% YoY
|
| EBIT |
-41.42M
est: -14.12M (-193.4%)
|
-70.21M
est: -42.95M (-63.5%)
|
-120.80M
est: -25.98M (-365.0%)
|
-188.40M
est: -219.99M (+14.4%)
|
-263.20M
est: -219.18M (-20.1%)
|
-401.50M
est: -79.43M (-405.5%)
|
-250.20M
est: -225.36M (-11.0%)
|
-80.50M
est: -246.39M (+67.3%)
|
-80.16M
-131.49M – -37.57M
+67.5% YoY
|
-69.16M
-106.97M – -27.88M
+13.7% YoY
|
-95.95M
-174.15M – -34.92M
-38.7% YoY
|
-149.96M
-272.16M – -54.58M
-56.3% YoY
|
-209.92M
-380.99M – -76.40M
-40.0% YoY
|
| Net Income |
-41.48M
est: -114.32M (+63.7%)
|
-70.29M
est: -139.84M (+49.7%)
|
-119.30M
est: -198.68M (+40.0%)
|
-191.00M
est: -215.82M (+11.5%)
|
-282.50M
est: -297.60M (+5.1%)
|
-367.30M
est: -323.40M (-13.6%)
|
-198.90M
est: -216.00M (+7.9%)
|
-80.80M
est: -39.09M (-106.7%)
|
-232.24M
-282.55M – -180.18M
-494.1% YoY
|
-260.46M
-290.30M – -132.78M
-12.1% YoY
|
-187.75M
-239.97M – -135.53M
+27.9% YoY
|
-147.69M
-304.16M – -25.57M
+21.3% YoY
|
-92.44M
-190.37M – -16.00M
+37.4% YoY
|
| SGA |
12.93M
est: 14.66M (-11.8%)
|
27.31M
est: 44.60M (-38.8%)
|
38.30M
est: 26.97M (+42.0%)
|
61.60M
est: 70.15M (-12.2%)
|
79.60M
est: 74.85M (+6.3%)
|
100.30M
est: 74.66M (+34.3%)
|
165.40M
est: 211.84M (-21.9%)
|
89.40M
est: 231.61M (-61.4%)
|
75.35M
35.31M – 123.60M
-67.5% YoY
|
65.01M
26.21M – 100.56M
-13.7% YoY
|
90.20M
32.83M – 163.70M
+38.7% YoY
|
140.96M
51.30M – 255.84M
+56.3% YoY
|
197.33M
71.82M – 358.14M
+40.0% YoY
|
| EPS |
-1.31
est: -1.59 (+17.6%)
|
-1.89
est: -1.94 (+2.8%)
|
-3.02
est: -2.76 (-9.3%)
|
-3.82
est: -3.56 (-7.2%)
|
-5.31
est: -4.94 (-7.5%)
|
-6.62
est: -5.00 (-32.3%)
|
-2.77
est: -3.15 (+12.0%)
|
-1.28
est: -0.71 (-79.8%)
|
-3.42
-4.35 – -2.78
-380.1% YoY
|
-3.50
-4.47 – -2.05
-2.3% YoY
|
-2.84
-3.70 – -2.09
+18.9% YoY
|
-2.28
-4.69 – -0.39
+19.7% YoY
|
-1.42
-2.93 – -0.25
+37.4% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-04 | Citigroup | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-297.33M
OE per share TTM
-4.31
Owner's Yield
-48.09%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
12.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
43
Total invested
21.78M
Insider transactions (90d)
0
Beneficial owners (>5%)
26
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Abigail P. Johnson | 4.48M | 11.42% | 251.6K | — | 4.48M | — | IN | Delaware | 2020-10-13 | ↗ |
| 2 | FMR LLC | 4.48M | 11.42% | 251.6K | — | 4.48M | — | HC | Delaware | 2020-10-13 | ↗ |
| 3 | RTW Investments, LP | 4.21M | 6.20% | — | 4.21M | — | — | IA, PN | Delaware | 2024-02-14 | ↗ |
| 4 | Roderick Wong, M.D. | 4.21M | 6.20% | — | 4.21M | — | — | HC, IN | United States | 2024-02-14 | ↗ |
| 5 | The Vanguard Group - 23-1945930 | 3.99M | 7.55% | — | 87.4K | — | 123.7K | IA | Pennsylvania | 2022-02-09 | ↗ |
| 6 | 52-0556948 | 3.84M | 5.60% | 824.9K | — | 3.83M | — | IA | — | 2024-02-14 | ↗ |
| 7 | (1) BlackRock, Inc. | 3.51M | 6.60% | 3.45M | — | 3.51M | — | HC | Delaware | 2022-02-03 | ↗ |
| 8 | PFIZER INC. | 3.46M | 6.60% | 3.46M | — | 3.46M | — | CO | Citizenship or Place of Organization Delaware | 2021-09-20 | ↗ |
| 9 | Avidity Capital Partners (GP) LLC | 3.24M | 6.10% | — | 3.24M | — | 3.24M | OO | Delaware | 2022-06-16 | ↗ |
| 10 | Avidity Capital Partners Fund (GP) LP | 3.24M | 6.10% | — | 3.24M | — | 3.24M | PN, OO | Delaware | 2022-06-16 | ↗ |
| 11 | Avidity Partners Management (GP) LLC | 3.24M | 6.10% | — | 3.24M | — | 3.24M | OO | Delaware | 2022-06-16 | ↗ |
| 12 | Avidity Partners Management LP | 3.24M | 6.10% | — | 3.24M | — | 3.24M | IA, PN | Delaware | 2022-06-16 | ↗ |
| 13 | David Witzke | 3.24M | 6.10% | — | 3.24M | — | 3.24M | IN | Delaware | 2022-06-16 | ↗ |
| 14 | Michael Gregory | 3.24M | 6.10% | — | 3.24M | — | 3.24M | IN | Delaware | 2022-06-16 | ↗ |
| 15 | EcoR1 Capital, LLC | 3.12M | 11.00% | — | 3.12M | — | 3.12M | IA, OO | Delaware | 2022-05-16 | ↗ |
| 16 | Oleg Nodelman | 3.12M | 11.00% | — | 3.12M | — | 3.12M | HC, IN | Delaware | 2022-05-16 | ↗ |
| 17 | EcoR1 Capital Fund Qualified, L.P. | 2.91M | 11.00% | — | — | 2.91M | 2.91M | PN | Delaware | 2022-05-16 | ↗ |
| 18 | Avidity Master Fund LP | 2.67M | 5.00% | — | 2.67M | — | 2.67M | PN, OO | Delaware | 2022-06-16 | ↗ |
| 19 | Craig Martin Crews | 1.38M | 2.86% | 1.38M | — | 1.38M | — | IN | United States America | 2021-02-16 | ↗ |
| 20 | New Leaf Venture Management III, L.L.C. | 1.08M | 2.00% | 1.08M | 5.00 | 1.08M | 7.00 | OO | Delaware | 2022-02-11 | ↗ |
| 21 | New Leaf Ventures III, L.P. (“NLV III”) | 1.08M | 2.00% | 1.08M | 5.00 | 1.08M | 7.00 | PN | Delaware | 2022-02-11 | ↗ |
| 22 | Canaan IX L.P. | — | 0.00% | — | — | — | — | PN | Cayman Islands | 2022-01-27 | ↗ |
| 23 | Canaan Partners IX LLC | — | 0.00% | — | — | — | — | OO | Cayman Islands | 2022-01-27 | ↗ |
| 24 | Peter Kolchinsky | — | 0.00% | — | — | — | — | HC, IN | Delaware | 2021-02-10 | ↗ |
| 25 | RA Capital Management, L.P. | — | 0.00% | — | — | — | — | IA, PN | Delaware | 2021-02-10 | ↗ |
| 26 | Rajeev Shah | — | 0.00% | — | — | — | — | HC, IN | Delaware | 2021-02-10 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
43
-166 vs prev Q
New positions
4
Closed positions
162
Increased
22
Reduced
10
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 180.0K +180.0K (+100.0%) | 2.14B +2.1B (+100.0%) | 0.25% +0.247 pp | 0.00% +0.003 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 2 | BLACKROCK, INC. | 7.32M +519.6K (+7.6%) | 86.84M +28.9M (+49.8%) | 10.04% +0.700 pp | 0.00% +0.001 pp | USD22.00 -46.1% | 6 qtrs — |
| 3 | VANGUARD GROUP INC | 7.23M -1.3M (-15.6%) | 85.74M +12.8M (+17.6%) | 9.92% -1.843 pp | 0.00% +0.000 pp | USD38.98 -69.6% | 29 qtrs — |
| 4 | D. E. SHAW & CO., INC. | 3.69M +342.0K (+10.2%) | 43.75M +15.2M (+53.4%) | 5.06% +0.463 pp | 0.02% +0.008 pp | USD8.15 +45.5% | 3 qtrs — |
| 5 | PFIZER INC | 3.46M +— (+0.0%) | 41.01M +11.5M (+39.2%) | 4.74% -0.007 pp | 17.34% +10.608 pp | USD19.17 -38.1% | 5 qtrs — |
| 6 | TCG CROSSOVER MANAGEMENT, LLC | 2.67M +1.0M (+64.8%) | 31.62M +17.8M (+129.5%) | 3.66% +1.436 pp | 1.05% +0.369 pp | USD9.83 +20.7% | 2 qtrs — |
| 7 | POINT72 ASSET MANAGEMENT, L.P. | 2.32M +2.3M (+100.0%) | 27.46M +27.5M (+100.0%) | 3.18% +3.176 pp | 0.03% +0.031 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 8 | STATE STREET CORP | 1.84M -29.7K (-1.6%) | 21.86M +5.9M (+37.0%) | 2.53% -0.044 pp | 0.00% +0.000 pp | USD33.40 -64.5% | 29 qtrs — |
| 9 | ARMISTICE CAPITAL, LLC | 1.80M +600.0K (+50.0%) | 21.35M +11.1M (+108.8%) | 2.47% +0.821 pp | 0.25% +0.102 pp | USD9.27 +27.9% | 3 qtrs — |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1.62M -46.7K (-2.8%) | 19.26M +5.0M (+35.3%) | 2.23% -0.067 pp | 0.00% +0.000 pp | USD40.42 -70.7% | 29 qtrs — |
| 11 | QUBE RESEARCH & TECHNOLOGIES LTD | 1.32M -162.1K (-10.9%) | 15.71M +3.0M (+24.0%) | 1.82% -0.225 pp | 0.02% +0.003 pp | USD9.27 +27.9% | 9 qtrs — |
| 12 | MILLENNIUM MANAGEMENT LLC | 1.26M -872.1K (-40.9%) | 14.94M -3.2M (-17.8%) | 1.73% -1.200 pp | 0.01% -0.002 pp | USD9.72 +22.0% | 30 qtrs — |
| 13 | ACADIAN ASSET MANAGEMENT LLC | 1.19M -277.4K (-18.9%) | 14.07M +1.6M (+12.8%) | 1.63% -0.383 pp | 0.02% +0.001 pp | USD7.35 +61.4% | 6 qtrs — |
| 14 | GOLDMAN SACHS GROUP INC | 1.12M +379.6K (+51.5%) | 13.24M +7.0M (+110.9%) | 1.53% +0.519 pp | 0.00% +0.001 pp | USD19.54 -39.3% | 30 qtrs — |
| 15 | FEDERATED HERMES, INC. | 1.09M +414.1K (+60.8%) | 12.99M +7.2M (+123.9%) | 1.50% +0.567 pp | 0.02% +0.012 pp | USD9.48 +25.1% | 10 qtrs — |
| 16 | TWO SIGMA INVESTMENTS, LP | 992.5K +992.5K (+100.0%) | 11.77M +11.8M (+100.0%) | 1.36% +1.361 pp | 0.02% +0.017 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 17 | MORGAN STANLEY | 810.1K -852.1K (-51.3%) | 9.61M -4.6M (-32.2%) | 1.11% -1.172 pp | 0.00% 0.000 pp | USD19.51 -39.2% | 29 qtrs — |
| 18 | TWO SIGMA ADVISERS, LP | 619.9K +607.0K (+4,705.4%) | 7.35M +7.2M (+6,589.2%) | 0.85% +0.833 pp | 0.01% +0.014 pp | USD11.79 +0.6% | 12 qtrs — |
| 19 | TANG CAPITAL MANAGEMENT LLC | 569.7K -824.1K (-59.1%) | 6.76M -5.1M (-43.1%) | 0.78% -1.133 pp | 0.33% -0.123 pp | USD7.02 +68.9% | 14 qtrs — |
| 20 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 547.5K -62.3K (-10.2%) | 6.49M +1.3M (+25.0%) | 0.75% -0.087 pp | 0.00% +0.000 pp | USD36.67 -67.7% | 29 qtrs — |
| 21 | NORTHERN TRUST CORP | 547.5K -51.7K (-8.6%) | 6.49M +1.4M (+27.2%) | 0.75% -0.072 pp | 0.00% +0.000 pp | USD32.47 -63.5% | 29 qtrs — |
| 22 | NEXTECH INVEST, LTD. | 539.4K -869.0K (-61.7%) | 6.40M -5.6M (-46.7%) | 0.74% -1.195 pp | 0.62% -1.208 pp | USD7.02 +68.9% | 4 qtrs — |
| 23 | NORDEA INVESTMENT MANAGEMENT AB | 495.5K -62.3K (-11.2%) | 5.89M +1.2M (+24.6%) | 0.68% -0.087 pp | 0.01% +0.001 pp | USD18.75 -36.7% | 16 qtrs — |
| 24 | DIMENSIONAL FUND ADVISORS LP | 472.4K -193.3K (-29.0%) | 5.60M -70.0K (-1.2%) | 0.65% -0.267 pp | 0.00% +0.000 pp | USD23.02 -48.5% | 12 qtrs — |
| 25 | CAXTON ASSOCIATES LLP | 454.5K -150.3K (-24.8%) | 5.39M +237.8K (+4.6%) | 0.62% -0.207 pp | 0.11% -0.016 pp | USD7.95 +49.2% | 3 qtrs — |
| 26 | ARBITER PARTNERS CAPITAL MANAGEMENT LLC | 452.8K +— (+0.0%) | 5.37M +1.5M (+39.2%) | 0.62% -0.001 pp | 2.62% +0.314 pp | USD8.52 +39.2% | 2 qtrs — |
| 27 | KENNEDY CAPITAL MANAGEMENT LLC | 442.8K +75.0 (+0.0%) | 5.25M +1.5M (+39.2%) | 0.61% -0.001 pp | 0.11% +0.028 pp | USD16.76 -29.2% | 8 qtrs — |
| 28 | CITADEL ADVISORS LLC | 413.6K +262.2K (+173.1%) | 4.91M +3.6M (+280.2%) | 0.57% +0.359 pp | 0.00% +0.001 pp | USD18.25 -35.0% | 25 qtrs — |
| 29 | RANGELEY CAPITAL, LLC | 395.8K -299.6K (-43.1%) | 4.69M -1.2M (-20.8%) | 0.54% -0.412 pp | 3.90% -1.228 pp | USD7.10 +67.0% | 4 qtrs — |
| 30 | TREXQUANT INVESTMENT LP | 394.7K +394.7K (+100.0%) | 4.68M +4.7M (+100.0%) | 0.54% +0.542 pp | 0.04% +0.042 pp | USD11.86 +0.0% | 3 qtrs — |
| 31 | IKARIAN CAPITAL, LLC | 358.3K +132.0K (+58.3%) | 4.25M +2.3M (+120.4%) | 0.49% +0.181 pp | 0.33% +0.137 pp | USD8.96 +32.4% | 4 qtrs — |
| 32 | MARSHALL WACE, LLP | 332.5K +94.6K (+39.8%) | 3.94M +1.9M (+94.6%) | 0.46% +0.129 pp | 0.00% +0.002 pp | USD9.84 +20.5% | 12 qtrs — |
| 33 | AQR CAPITAL MANAGEMENT LLC | 319.0K +95.2K (+42.5%) | 3.78M +1.9M (+98.4%) | 0.44% +0.130 pp | 0.00% +0.001 pp | USD8.66 +37.0% | 4 qtrs — |
| 34 | JANE STREET GROUP, LLC | 309.1K -154.2K (-33.3%) | 3.67M -281.6K (-7.1%) | 0.42% -0.212 pp | 0.00% +0.000 pp | USD8.52 +39.2% | 23 qtrs — |
| 35 | INVESCO LTD. | 302.1K +64.0K (+26.9%) | 3.58M +1.6M (+76.7%) | 0.41% +0.087 pp | 0.00% +0.000 pp | USD13.45 -11.8% | 25 qtrs — |
| 36 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 301.2K +27.6K (+10.1%) | 3.57M +1.2M (+53.2%) | 0.41% +0.037 pp | 0.06% +0.018 pp | USD8.83 +34.3% | 2 qtrs — |
| 37 | NANTAHALA CAPITAL MANAGEMENT, LLC | 300.0K +300.0K (+100.0%) | 3.56M +3.6M (+100.0%) | 0.41% +0.412 pp | 0.12% +0.118 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 38 | WASATCH ADVISORS LP | 269.1K -237.7K (-46.9%) | 3.19M -1.1M (-26.1%) | 0.37% -0.327 pp | 0.02% -0.004 pp | USD7.48 +58.6% | 20 qtrs — |
| 39 | BANK OF NEW YORK MELLON CORP | 268.6K +62.9K (+30.6%) | 3.19M +1.4M (+81.8%) | 0.37% +0.086 pp | 0.00% +0.000 pp | USD34.28 -65.4% | 28 qtrs — |
| 40 | BALYASNY ASSET MANAGEMENT L.P. | 261.8K -945.5K (-78.3%) | 3.10M -7.2M (-69.8%) | 0.36% -1.299 pp | 0.00% -0.009 pp | USD8.26 +43.6% | 4 qtrs — |
| 41 | HRT FINANCIAL LP | 261.0K -135.9K (-34.2%) | 3.10M -286.0K (-8.5%) | 0.36% -0.187 pp | 0.01% -0.003 pp | USD8.08 +46.8% | 6 qtrs — |
| 42 | JACOBS LEVY EQUITY MANAGEMENT, INC | 252.3K +29.8K (+13.4%) | 2.99M +1.1M (+57.9%) | 0.35% +0.041 pp | 0.01% +0.004 pp | USD8.05 +47.3% | 4 qtrs — |
| 43 | FRANKLIN RESOURCES INC | 203.9K -53.8K (-20.9%) | 2.42M +222.6K (+10.1%) | 0.28% -0.074 pp | 0.00% +0.000 pp | USD10.38 +14.3% | 9 qtrs — |
| 44 | ALGERT GLOBAL LLC | 195.0K -48.3K (-19.8%) | 2.31M +240.0K (+11.6%) | 0.27% -0.067 pp | 0.04% +0.001 pp | USD10.98 +8.0% | 12 qtrs — |
| 45 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 188.9K -52.6K (-21.8%) | 2.24M +182.9K (+8.9%) | 0.26% -0.073 pp | 0.02% -0.004 pp | USD8.52 +39.2% | 4 qtrs — |
| 46 | JUMP FINANCIAL, LLC | 188.3K +188.3K (+100.0%) | 2.23M +2.2M (+100.0%) | 0.26% +0.258 pp | 0.03% +0.027 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 47 | VOLEON CAPITAL MANAGEMENT LP | 185.0K +32.9K (+21.7%) | 2.19M +898.3K (+69.3%) | 0.25% +0.045 pp | 0.05% +0.016 pp | USD9.11 +30.2% | 2 qtrs — |
| 48 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 173.9K -159.8K (-47.9%) | 2.06M -780.7K (-27.5%) | 0.24% -0.220 pp | 0.00% 0.000 pp | USD7.98 +48.6% | 25 qtrs — |
| 49 | BARCLAYS PLC | 168.4K +46.7K (+38.4%) | 2.00M -1.0M (-33.4%) | 0.23% +0.064 pp | 0.00% 0.000 pp | USD17.36 -31.7% | 30 qtrs — |
| 50 | UBS GROUP AG | 166.9K -233.2K (-58.3%) | 1.98M -1.4M (-41.9%) | 0.23% -0.321 pp | 0.00% 0.000 pp | USD15.60 -24.0% | 29 qtrs — |
| 51 | BRUMMER MULTI-STRATEGY AB | 166.3K +166.3K (+100.0%) | 1.97M +2.0M (+100.0%) | 0.23% +0.228 pp | 11.93% +11.925 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 52 | DEKABANK DEUTSCHE GIROZENTRALE | 42.0K +— (+0.0%) | 1.89M +19.0K (+1.0%) | 0.06% 0.000 pp | 0.00% +0.000 pp | USD42.40 -72.0% | 22 qtrs — |
| 53 | BANK OF AMERICA CORP /DE/ | 154.3K -100.1K (-39.3%) | 1.83M -337.4K (-15.6%) | 0.21% -0.138 pp | 0.00% +0.000 pp | USD12.49 -5.0% | 29 qtrs — |
| 54 | ZACKS INVESTMENT MANAGEMENT | 148.7K -9.4K (-5.9%) | 1.76M +416.8K (+30.9%) | 0.20% -0.013 pp | 0.01% +0.003 pp | USD24.77 -52.1% | 9 qtrs — |
| 55 | DEUTSCHE BANK AG\ | 145.3K -47.3K (-24.5%) | 1.72M +82.6K (+5.0%) | 0.20% -0.065 pp | 0.00% +0.000 pp | USD39.89 -70.3% | 29 qtrs — |
| 56 | NUVEEN, LLC | 142.8K +— (+0.0%) | 1.69M +476.9K (+39.2%) | 0.20% 0.000 pp | 0.00% +0.000 pp | USD7.02 +68.9% | 4 qtrs — |
| 57 | Y-INTERCEPT (HONG KONG) LTD | 124.8K -158.7K (-56.0%) | 1.48M -935.2K (-38.7%) | 0.17% -0.218 pp | 0.03% -0.025 pp | USD7.92 +49.7% | 3 qtrs — |
| 58 | UBS ASSET MANAGEMENT AMERICAS INC | 124.3K -791.0 (-0.6%) | 1.47M +408.5K (+38.3%) | 0.17% -0.001 pp | 0.00% +0.000 pp | USD20.19 -41.3% | 25 qtrs — |
| 59 | SWISS NATIONAL BANK | 123.1K +9.9K (+8.7%) | 1.46M +495.5K (+51.4%) | 0.17% +0.013 pp | 0.00% +0.000 pp | USD40.92 -71.0% | 27 qtrs — |
| 60 | LPL FINANCIAL LLC | 111.2K -8.5K (-7.1%) | 1.32M +299.1K (+29.3%) | 0.15% -0.012 pp | 0.00% +0.000 pp | USD12.14 -2.3% | 9 qtrs — |
| 61 | HUSSMAN STRATEGIC ADVISORS, INC. | 105.0K +105.0K (+100.0%) | 1.25M +1.2M (+100.0%) | 0.14% +0.144 pp | 0.30% +0.301 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 62 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 101.8K +69.7K (+217.2%) | 1.21M +934.3K (+341.6%) | 0.14% +0.096 pp | 0.00% +0.002 pp | USD10.44 +13.6% | 3 qtrs — |
| 63 | WELLS FARGO & COMPANY/MN | 101.5K +17.9K (+21.3%) | 1.20M +491.1K (+68.9%) | 0.14% +0.024 pp | 0.00% +0.000 pp | USD21.76 -45.5% | 29 qtrs — |
| 64 | MAN GROUP PLC | 99.9K +48.5K (+94.6%) | 1.18M +747.2K (+170.8%) | 0.14% +0.067 pp | 0.00% +0.001 pp | USD9.37 +26.6% | 6 qtrs — |
| 65 | VERITION FUND MANAGEMENT LLC | 92.0K +12.0K (+15.1%) | 1.09M +409.9K (+60.2%) | 0.13% +0.016 pp | 0.00% +0.002 pp | USD15.03 -21.1% | 12 qtrs — |
| 66 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 91.0K +91.0K (+100.0%) | 1.08M +1.1M (+100.0%) | 0.12% +0.125 pp | 0.00% +0.004 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 67 | RHUMBLINE ADVISERS | 87.2K -12.2K (-12.3%) | 1.03M +187.5K (+22.1%) | 0.12% -0.017 pp | 0.00% +0.000 pp | USD33.70 -64.8% | 27 qtrs — |
| 68 | HEADLANDS TECHNOLOGIES LLC | 86.2K +73.3K (+569.5%) | 1.02M +912.8K (+832.0%) | 0.12% +0.101 pp | 0.09% +0.077 pp | USD11.36 +4.4% | 12 qtrs — |
| 69 | BOOTHBAY FUND MANAGEMENT, LLC | 82.5K +17.6K (+27.1%) | 978.2K +425.2K (+76.9%) | 0.11% +0.024 pp | 0.01% +0.007 pp | USD8.25 +43.8% | 4 qtrs — |
| 70 | FOX RUN MANAGEMENT, L.L.C. | 82.1K +23.0K (+38.8%) | 974.0K +469.9K (+93.2%) | 0.11% +0.031 pp | 0.15% +0.072 pp | USD9.45 +25.5% | 2 qtrs — |
| 71 | PRICE T ROWE ASSOCIATES INC /MD/ | 81.6K -5.8K (-6.6%) | 968.0K +224.0K (+30.1%) | 0.11% -0.008 pp | 0.00% +0.000 pp | USD50.62 -76.6% | 27 qtrs — |
| 72 | SG AMERICAS SECURITIES, LLC | 78.2K +39.9K (+104.3%) | 927.0K +601.0K (+184.4%) | 0.11% +0.055 pp | 0.00% +0.000 pp | USD9.66 +22.8% | 25 qtrs — |
| 73 | HSBC HOLDINGS PLC | 73.8K +11.7K (+18.8%) | 875.7K +352.3K (+67.3%) | 0.10% +0.016 pp | 0.00% +0.000 pp | USD13.73 -13.6% | 8 qtrs — |
| 74 | ALLIANCEBERNSTEIN L.P. | 73.7K +— (+0.0%) | 874.3K +246.2K (+39.2%) | 0.10% 0.000 pp | 0.00% +0.000 pp | USD34.43 -65.6% | 27 qtrs — |
| 75 | PLATINUM INVESTMENT MANAGEMENT LTD | 72.5K -14.4K (-16.6%) | 860.2K +119.5K (+16.1%) | 0.10% -0.020 pp | 0.20% +0.151 pp | USD8.52 +39.2% | 2 qtrs — |
| 76 | VIRGINIA RETIREMENT SYSTEMS ET AL | 70.7K +55.7K (+371.0%) | 837.9K +710.1K (+555.6%) | 0.10% +0.076 pp | 0.01% +0.004 pp | USD11.15 +6.4% | 4 qtrs — |
| 77 | MONACO ASSET MANAGEMENT SAM | 70.3K -640.7K (-90.1%) | 833.2K -5.2M (-86.2%) | 0.10% -0.880 pp | 0.14% -0.223 pp | USD7.58 +56.5% | 5 qtrs — |
| 78 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 68.1K +68.1K (+100.0%) | 807.2K +807.2K (+100.0%) | 0.09% +0.093 pp | 0.01% +0.010 pp | USD11.86 +0.0% | 1 qtrs NEW |
| 79 | QUANTINNO CAPITAL MANAGEMENT LP | 66.2K +14.5K (+27.9%) | 785.7K +344.5K (+78.1%) | 0.09% +0.020 pp | 0.00% +0.000 pp | USD8.71 +36.2% | 3 qtrs — |
| 80 | LEGAL & GENERAL GROUP PLC | 60.5K +8.7K (+16.8%) | 717.8K +276.5K (+62.6%) | 0.08% +0.012 pp | 0.00% +0.000 pp | USD52.55 -77.4% | 21 qtrs — |
| 81 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 60.5K -659.0 (-1.1%) | 717.8K +196.5K (+37.7%) | 0.08% -0.001 pp | 0.00% +0.000 pp | USD33.25 -64.3% | 29 qtrs — |
| 82 | ADAR1 CAPITAL MANAGEMENT, LLC | 58.1K -24.5K (-29.7%) | 689.0K -14.7K (-2.1%) | 0.08% -0.034 pp | 0.05% -0.016 pp | USD7.02 +68.9% | 8 qtrs — |
| 83 | ENGINEERS GATE MANAGER LP | 58.1K +58.1K (+100.0%) | 688.7K +688.7K (+100.0%) | 0.08% +0.080 pp | 0.01% +0.008 pp | USD11.86 +0.0% | 27 qtrs — |
| 84 | VIENNA POWSZECHNE TOWARZYSTWO EMERYTALNE S.A. VIENNA INSURANCE GROUP | 57.5K +— (+0.0%) | 682.0K +192.1K (+39.2%) | 0.08% 0.000 pp | 0.33% +0.043 pp | USD79.20 -85.0% | 18 qtrs — |
| 85 | CREATIVE PLANNING | 56.9K +12.1K (+27.0%) | 675.2K +293.2K (+76.7%) | 0.08% +0.017 pp | 0.00% +0.000 pp | USD8.66 +37.0% | 5 qtrs — |
| 86 | AMERICAN CENTURY COMPANIES INC | 53.5K +22.6K (+73.0%) | 634.5K +371.0K (+140.8%) | 0.07% +0.031 pp | 0.00% +0.000 pp | USD9.43 +25.8% | 24 qtrs — |
| 87 | NEOS INVESTMENT MANAGEMENT LLC | 49.5K +49.5K (+100.0%) | 587.4K +587.4K (+100.0%) | 0.07% +0.068 pp | 0.00% +0.003 pp | USD11.86 +0.0% | 9 qtrs — |
| 88 | TEMA ETFS LLC | 48.8K +48.8K (+100.0%) | 578.8K +578.8K (+100.0%) | 0.07% +0.067 pp | 0.04% +0.045 pp | USD11.86 +0.0% | 5 qtrs — |
| 89 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 47.9K -87.4K (-64.6%) | 567.5K -584.7K (-50.7%) | 0.07% -0.120 pp | 0.01% +0.001 pp | USD8.52 +39.2% | 2 qtrs — |
| 90 | YELIN LAPIDOT HOLDINGS MANAGEMENT LTD. | 46.7K +— (+0.0%) | 553.4K +155.9K (+39.2%) | 0.06% 0.000 pp | 0.11% +0.027 pp | USD19.64 -39.6% | 10 qtrs — |
| 91 | ALLSPRING GLOBAL INVESTMENTS HOLDINGS, LLC | 46.6K +4.1K (+9.6%) | 552.4K +190.3K (+52.5%) | 0.06% +0.006 pp | 0.00% +0.000 pp | USD7.67 +54.6% | 17 qtrs — |
| 92 | CITIGROUP INC | 42.3K +19.8K (+88.3%) | 501.7K +310.3K (+162.1%) | 0.06% +0.027 pp | 0.00% +0.000 pp | USD14.13 -16.1% | 30 qtrs — |
| 93 | GSA CAPITAL PARTNERS LLP | 42.1K +27.3K (+185.3%) | 499.0K +373.0K (+296.0%) | 0.06% +0.038 pp | 0.04% +0.033 pp | USD10.21 +16.2% | 4 qtrs — |
| 94 | QUEST PARTNERS LLC | 41.5K +15.0K (+56.7%) | 491.7K +266.3K (+118.2%) | 0.06% +0.021 pp | 0.03% +0.013 pp | USD9.18 +29.2% | 7 qtrs — |
| 95 | QUINN OPPORTUNITY PARTNERS LLC | 41.3K -20.0K (-32.6%) | 489.4K -32.6K (-6.2%) | 0.06% -0.028 pp | 0.02% -0.016 pp | USD7.36 +61.1% | 3 qtrs — |
| 96 | AMERIPRISE FINANCIAL INC | 37.9K +110.0 (+0.3%) | 449.2K +127.4K (+39.6%) | 0.05% +0.000 pp | 0.00% +0.000 pp | USD7.37 +60.9% | 23 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 96 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Pharmaceuticals ETF XPH | 1.22% | 5.73M | 0.35% |
| 2 | Virtus Biotech Clinical Trials ETF BBC | 0.67% | 386.5K | 0.65% |
| 3 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.46% | 101.0K | 0.20% |
| 4 | Tema Oncology ETF CANC | 0.36% | 514.4K | 0.75% |
| 5 | Federated Hermes MDT Small Cap Core ETF FSCC | 0.27% | 449.8K | 0.51% |
| 6 | Direxion Daily Pharmaceutical & Medical Bull 3X ETF PILL | 0.25% | 58.9K | 1.22% |
| 7 | iShares U.S. Pharmaceuticals ETF IHE | 0.12% | 1.61M | 0.38% |
| 8 | WisdomTree U.S. SmallCap Fund EES | 0.09% | 643.8K | 0.38% |
| 9 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.06% | 711.9K | 0.40% |
| 10 | Franklin Small Cap Enhanced ETF FSML | 0.06% | 88.1K | 0.45% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.86
Neutral
Ratio by volume
3.00
Bullish
Buys
12
Sells
14
Shares acquired
900.6K
Shares disposed
72.1K
Cash buys
1.00
Cash sales
14.00
Net activity
+828,520
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-18 | Berkowitz Noah | Officer | S-Sale | D | Common Stock | 6,435 | 11.10 | 71.4K | 202,503 | D | ↗ |
| 2026-03-06 | Morrison Briggs | Director | P-Purchase | A | Common Stock | 20,000 | 13.40 | 268.1K | 96,021 | D | ↗ |
| 2026-02-27 | Houston John G | Director | S-Sale | D | Common Stock | 11,787 | 13.14 | 154.9K | 1,122,183 | D | ↗ |
| 2026-02-26 | Teel Randy | Director / Officer | A-Award | A | Stock Option (right to buy) | 218,691 | 13.38 | 2.93M | 218,691 | D | ↗ |
| 2026-02-26 | Saik Andrew | Officer | A-Award | A | Common Stock | 45,000 | 0.00 | — | 204,267 | D | ↗ |
| 2026-02-26 | Loomis David K | Officer | A-Award | A | Stock Option (right to buy) | 18,504 | 13.38 | 247.6K | 18,504 | D | ↗ |
| 2026-02-26 | Cacace Angela M | Officer | A-Award | A | Stock Option (right to buy) | 67,000 | 13.38 | 896.5K | 67,000 | D | ↗ |
| 2026-02-26 | Berkowitz Noah | Officer | A-Award | A | Stock Option (right to buy) | 67,000 | 13.38 | 896.5K | 67,000 | D | ↗ |
| 2026-02-23 | Teel Randy | Director / Officer | S-Sale | D | Common Stock | 3,748 | 12.16 | 45.6K | 149,696 | D | ↗ |
| 2026-02-23 | Loomis David K | Officer | S-Sale | D | Common Stock | 1,108 | 12.16 | 13.5K | 29,692 | D | ↗ |
| 2026-02-23 | Cacace Angela M | Officer | S-Sale | D | Common Stock | 2,571 | 12.16 | 31.3K | 147,623 | D | ↗ |
| 2026-02-13 | Teel Randy | Director / Officer | S-Sale | D | Common Stock | 4,403 | 11.89 | 52.4K | 154,482 | D | ↗ |
| 2026-02-13 | Saik Andrew | Officer | S-Sale | D | Common Stock | 5,134 | 11.89 | 61.0K | 159,267 | D | ↗ |
| 2026-02-13 | Loomis David K | Officer | S-Sale | D | Common Stock | 1,016 | 11.89 | 12.1K | 30,800 | D | ↗ |
| 2026-02-13 | Cacace Angela M | Officer | S-Sale | D | Common Stock | 4,592 | 11.89 | 54.6K | 151,232 | D | ↗ |
| 2026-02-13 | Berkowitz Noah | Officer | S-Sale | D | Common Stock | 5,685 | 11.89 | 67.6K | 163,938 | D | ↗ |
| 2026-02-12 | Teel Randy | Director / Officer | — | — | Stock Option (right to buy) | 91,000 | 6.61 | 601.5K | 0 | D | ↗ |
| 2025-11-07 | Loomis David K | Officer | S-Sale | D | Common Stock | 230 | 9.89 | 2.3K | 31,697 | D | ↗ |
| 2025-09-22 | Morrison Briggs | Director | P-Purchase | A | Common Stock | 30,000 | 7.57 | 227.0K | 76,021 | D | ↗ |
| 2025-06-25 | YOUNG JOHN D | Director | A-Award | A | Stock Option (right to buy) | 23,105 | 7.80 | 180.2K | 23,105 | D | ↗ |
| 2025-06-25 | Smaldone Alsup Laurie | Director | A-Award | A | Stock Option (right to buy) | 23,105 | 7.80 | 180.2K | 23,105 | D | ↗ |
| 2025-06-25 | Norwalk Leslie V | Director | A-Award | A | Stock Option (right to buy) | 23,105 | 7.80 | 180.2K | 23,105 | D | ↗ |
| 2025-06-25 | Morrison Briggs | Director | A-Award | A | Common Stock | 16,025 | 0.00 | — | 46,021 | D | ↗ |
| 2025-06-25 | Kennedy Edward Moore Jr. | Director | A-Award | A | Stock Option (right to buy) | 23,105 | 7.80 | 180.2K | 23,105 | D | ↗ |
| 2025-06-25 | Cunningham Everett | Director | A-Award | A | Stock Option (right to buy) | 23,105 | 7.80 | 180.2K | 23,105 | D | ↗ |
| 2025-06-25 | Bain Linda | Director | A-Award | A | Stock Option (right to buy) | 23,105 | 7.80 | 180.2K | 23,105 | D | ↗ |
| 2025-06-25 | AGARWAL SUNIL | Director | A-Award | A | Stock Option (right to buy) | 23,105 | 7.80 | 180.2K | 23,105 | D | ↗ |
| 2025-06-24 | Saik Andrew | Officer | S-Sale | D | Common Stock | 5,700 | 7.61 | 43.4K | 164,401 | D | ↗ |
| 2025-06-17 | Cacace Angela M | Officer | S-Sale | D | Common Stock | 2,583 | 7.49 | 19.3K | 154,248 | D | ↗ |
| 2025-05-09 | Saik Andrew | Officer | A-Award | A | Stock Option (right to buy) | 91,000 | 6.61 | 601.5K | 91,000 | D | ↗ |
| 2025-05-09 | Loomis David K | Officer | A-Award | A | Stock Option (right to buy) | 18,100 | 6.61 | 119.6K | 18,100 | D | ↗ |
| 2025-05-09 | Cacace Angela M | Officer | A-Award | A | Common Stock | 59,600 | 0.00 | — | 156,831 | D | ↗ |
| 2025-05-09 | Berkowitz Noah | Officer | A-Award | A | Stock Option (right to buy) | 91,000 | 6.61 | 601.5K | 91,000 | D | ↗ |
| 2025-03-18 | Berkowitz Noah | Officer | S-Sale | D | Common Stock | 8,658 | 8.59 | 74.4K | 110,023 | D | ↗ |
| 2025-02-24 | Taylor Ian | Officer | S-Sale | D | Common Stock | 1,664 | 16.55 | 27.5K | 159,121 | D | ↗ |
| 2025-02-24 | Loomis David K | Officer | S-Sale | D | Common Stock | 1,214 | 16.75 | 20.3K | 18,863 | D | ↗ |
| 2025-02-24 | Houston John G | Director / Officer | S-Sale | D | Common Stock | 5,154 | 16.55 | 85.3K | 1,157,480 | D | ↗ |
| 2025-02-24 | Cacace Angela M | Officer | S-Sale | D | Common Stock | 1,146 | 16.55 | 19.0K | 97,231 | D | ↗ |
| 2025-02-13 | Taylor Ian | Officer | A-Award | A | Stock Option (right to buy) | 31,483 | 17.67 | 556.3K | 31,483 | D | ↗ |
| 2025-02-13 | Saik Andrew | Officer | A-Award | A | Stock Option (right to buy) | 74,960 | 17.67 | 1.32M | 74,960 | D | ↗ |
| 2025-02-13 | Loomis David K | Officer | A-Award | A | Stock Option (right to buy) | 16,176 | 17.67 | 285.8K | 16,176 | D | ↗ |
| 2025-02-13 | Houston John G | Director / Officer | A-Award | A | Stock Option (right to buy) | 232,000 | 17.67 | 4.10M | 232,000 | D | ↗ |
| 2025-02-13 | Cacace Angela M | Officer | A-Award | A | Stock Option (right to buy) | 74,960 | 17.67 | 1.32M | 74,960 | D | ↗ |
| 2025-02-13 | Berkowitz Noah | Officer | A-Award | A | Common Stock | 55,229 | 0.00 | — | 118,681 | D | ↗ |
| 2024-11-07 | Loomis David K | Officer | S-Sale | D | Common Stock | 231 | 27.69 | 6.4K | 8,040 | D | ↗ |
| 2024-06-24 | Saik Andrew | Officer | A-Award | A | Stock Option (right to buy) | 94,418 | 24.97 | 2.36M | 94,418 | — | ↗ |
| 2024-06-17 | Cacace Angela M | Officer | — | D | Stock Option (right to buy) | 52,400 | 64.19 | 3.36M | 0 | — | ↗ |
| 2024-05-29 | YOUNG JOHN D | Director | A-Award | A | Stock Option (right to buy) | 9,070 | 33.90 | 307.5K | 9,070 | — | ↗ |
| 2024-05-29 | Smaldone Alsup Laurie | Director | A-Award | A | Stock Option (right to buy) | 9,070 | 33.90 | 307.5K | 9,070 | — | ↗ |
| 2024-05-29 | Norwalk Leslie V | Director | A-Award | A | Stock Option (right to buy) | 9,070 | 33.90 | 307.5K | 9,070 | — | ↗ |
| 2024-05-29 | Morrison Briggs | Director | A-Award | A | Stock Option (right to buy) | 9,070 | 33.90 | 307.5K | 9,070 | — | ↗ |
| 2024-05-29 | Kennedy Edward Moore Jr. | Director | A-Award | A | Common Stock | 5,899 | 0.00 | — | 23,405 | — | ↗ |
| 2024-05-29 | Cunningham Everett | Director | A-Award | A | Stock Option (right to buy) | 9,070 | 33.90 | 307.5K | 9,070 | — | ↗ |
| 2024-05-29 | Bain Linda | Director | A-Award | A | Stock Option (right to buy) | 9,070 | 33.90 | 307.5K | 9,070 | — | ↗ |
| 2024-05-29 | AGARWAL SUNIL | Director | A-Award | A | Common Stock | 5,899 | 0.00 | — | 14,141 | — | ↗ |
| 2024-05-21 | Teel Randy | Officer | A-Award | A | Common Stock | 13,300 | 0.00 | — | 59,341 | — | ↗ |
| 2024-03-18 | Berkowitz Noah | Officer | A-Award | A | Stock Option (right to buy) | 93,879 | 42.60 | 4.00M | 93,879 | — | ↗ |
| 2024-02-29 | Teel Randy | Officer | — | D | Stock Option (right to buy) | 38,350 | 34.37 | 1.32M | 0 | — | ↗ |
| 2024-02-23 | Taylor Ian | Officer | A-Award | A | Stock Option (right to buy) | 58,100 | 47.00 | 2.73M | 58,100 | — | ↗ |
| 2024-02-23 | Peck Ronald | Officer | A-Award | A | Stock Option (right to buy) | 58,100 | 47.00 | 2.73M | 58,100 | — | ↗ |
| 2024-02-23 | Loomis David K | Officer | A-Award | A | Common Stock | 5,750 | 0.00 | — | 8,500 | — | ↗ |
| 2024-02-23 | Houston John G | Director / Officer | A-Award | A | Stock Option (right to buy) | 184,200 | 47.00 | 8.66M | 184,200 | — | ↗ |
| 2024-02-23 | Cassidy Sean A | Officer | S-Sale | D | Common Stock | 1,702 | 47.05 | 80.1K | 181,916 | — | ↗ |
| 2024-01-04 | Taylor Ian | Officer | M-Exempt | D | Stock Option (right to buy) | 0 | 16.00 | — | 2,065 | — | ↗ |
| 2023-11-08 | Loomis David K | Officer | S-Sale | D | Common Stock | 229 | 17.05 | 3.9K | 8,271 | D | ↗ |
| 2023-08-11 | Peck Ronald | Officer | M-Exempt | A | Common Stock | 4,010 | 0.00 | — | 31,289 | — | ↗ |
| 2023-06-15 | YOUNG JOHN D | Director | A-Award | A | Stock Option (right to buy) | 12,787 | 30.33 | 387.8K | 12,787 | — | ↗ |
| 2023-06-15 | Smaldone Alsup Laurie | Director | A-Award | A | Common Stock | 4,121 | 0.00 | — | 4,121 | — | ↗ |
| 2023-06-15 | Norwalk Leslie V | Director | A-Award | A | Stock Option (right to buy) | 12,787 | 30.33 | 387.8K | 12,787 | — | ↗ |
| 2023-06-15 | Morrison Briggs | Director | A-Award | A | Stock Option (right to buy) | 12,787 | 30.33 | 387.8K | 12,787 | — | ↗ |
| 2023-06-15 | Kennedy Edward Moore Jr. | Director | A-Award | A | Stock Option (right to buy) | 12,787 | 30.33 | 387.8K | 12,787 | — | ↗ |
| 2023-06-15 | DIXON WENDY L | Director | A-Award | A | Common Stock | 4,121 | 0.00 | — | 9,121 | — | ↗ |
| 2023-06-15 | Cunningham Everett | Director | A-Award | A | Common Stock | 4,121 | 0.00 | — | 4,121 | — | ↗ |
| 2023-06-15 | Bain Linda | Director | A-Award | A | Common Stock | 4,121 | 0.00 | — | 4,121 | — | ↗ |
| 2023-06-15 | AGARWAL SUNIL | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-03-01 | Taylor Ian | Officer | M-Exempt | A | Common Stock | 2,685 | 0.00 | — | 102,772 | — | ↗ |
| 2023-03-01 | Houston John G | Director / Officer | M-Exempt | A | Common Stock | 17,510 | 0.00 | — | 923,305 | — | ↗ |
| 2023-03-01 | Cassidy Sean A | Officer | M-Exempt | A | Common Stock | 4,791 | 0.00 | — | 185,363 | — | ↗ |
| 2023-02-22 | Taylor Ian | Officer | A-Award | A | Stock Option (right to buy) | 57,450 | 34.37 | 1.97M | 57,450 | — | ↗ |
| 2023-02-22 | Peck Ronald | Officer | A-Award | A | Common Stock | 19,125 | 0.00 | — | 27,279 | — | ↗ |
| 2023-02-22 | Houston John G | Director / Officer | A-Award | A | Stock Option (right to buy) | 186,250 | 34.37 | 6.40M | 186,250 | — | ↗ |
| 2023-02-22 | Cassidy Sean A | Officer | A-Award | A | Stock Option (right to buy) | 57,450 | 34.37 | 1.97M | 57,450 | — | ↗ |
| 2022-12-15 | Loomis David K | Officer | — | D | Stock Option (right to buy) | 27,500 | 41.39 | 1.14M | — | — | ↗ |
| 2022-12-15 | Cunningham Everett | Director | A-Award | A | Common Stock | 30,095 | 0.00 | — | 30,095 | — | ↗ |
| 2022-08-18 | YOUNG JOHN D | Director | A-Award | A | Stock Option (right to buy) | 24,572 | 0.00 | — | 24,572 | — | ↗ |
| 2022-08-12 | Peck Ronald | Officer | M-Exempt | A | Common Stock | 4,010 | 0.00 | — | 9,412 | — | ↗ |
| 2022-06-16 | Smaldone Alsup Laurie | Director | A-Award | A | Stock Option (right to buy) | 10,192 | 0.00 | — | 10,192 | — | ↗ |
| 2022-06-16 | SHANNON TIMOTHY M | Director | A-Award | A | Stock Option (right to buy) | 10,192 | 0.00 | — | 10,192 | — | ↗ |
| 2022-06-16 | Ratcliffe Liam | Director | A-Award | A | Stock Option (right to buy) | 10,192 | 0.00 | — | 10,192 | — | ↗ |
| 2022-06-16 | Norwalk Leslie V | Director | A-Award | A | Stock Option (right to buy) | 10,192 | 36.79 | 375.0K | 10,192 | — | ↗ |
| 2022-06-16 | Morrison Briggs | Director | A-Award | A | Stock Option (right to buy) | 10,192 | 0.00 | — | 10,192 | — | ↗ |
| 2022-06-16 | Margus Bradley Albert | Director | A-Award | A | Stock Option (right to buy) | 10,192 | 0.00 | — | 10,192 | — | ↗ |
| 2022-06-16 | Kennedy Edward Moore Jr. | Director | A-Award | A | Stock Option (right to buy) | 10,192 | 0.00 | — | 10,192 | — | ↗ |
| 2022-06-16 | DIXON WENDY L | Director | A-Award | A | Stock Option (right to buy) | 10,192 | 0.00 | — | 10,192 | — | ↗ |
| 2022-06-16 | Bain Linda | Director | A-Award | A | Stock Option (right to buy) | 10,192 | 0.00 | — | 10,192 | — | ↗ |
| 2022-04-14 | Morrison Briggs | Director | S-Sale | D | Common Stock | 7,104 | 66.07 | 469.4K | 30,730 | — | ↗ |
| 2022-03-31 | Taylor Ian | Officer | G-Gift | D | Common Stock | 3,000 | 0.00 | — | 80,962 | — | ↗ |
| 2022-03-11 | Cassidy Sean A | Officer | M-Exempt | A | Common Stock | 15,000 | 16.00 | 240.0K | 176,447 | — | ↗ |
| 2022-03-04 | Taylor Ian | Officer | M-Exempt | D | Restricted Stock Units | 2,686 | 0.00 | — | 2,685 | — | ↗ |
| 2022-03-04 | Houston John G | Director / Officer | M-Exempt | D | Restricted Stock Units | 17,511 | 0.00 | — | 17,510 | — | ↗ |
| 2022-03-04 | Cassidy Sean A | Officer | M-Exempt | D | Restricted Stock Units | 4,791 | 0.00 | — | 4,791 | — | ↗ |
| 2022-03-01 | Taylor Ian | Officer | M-Exempt | A | Common Stock | 3,500 | 16.00 | 56.0K | 82,145 | — | ↗ |
| 2022-02-23 | Taylor Ian | Officer | A-Award | A | Stock Option (right to buy) | 67,000 | 64.19 | 4.30M | 67,000 | — | ↗ |
| 2022-02-23 | Peck Ronald | Officer | A-Award | A | Stock Option (right to buy) | 67,000 | 64.19 | 4.30M | 67,000 | — | ↗ |
| 2022-02-23 | Houston John G | Director / Officer | A-Award | A | Stock Option (right to buy) | 200,500 | 64.19 | 12.87M | 200,500 | — | ↗ |
| 2022-02-23 | Cassidy Sean A | Officer | A-Award | A | Stock Option (right to buy) | 67,000 | 64.19 | 4.30M | 67,000 | — | ↗ |
| 2022-02-15 | Taylor Ian | Officer | M-Exempt | A | Common Stock | 20,000 | 19.36 | 387.2K | 98,645 | — | ↗ |
| 2022-01-14 | Morrison Briggs | Director | M-Exempt | D | Stock Option (right to buy) | 16,188 | 16.00 | 259.0K | 16,682 | — | ↗ |
| 2021-12-30 | Peck Ronald | Officer | M-Exempt | D | Stock Option (right to buy) | 5,625 | 26.58 | 149.5K | 46,559 | — | ↗ |
| 2021-12-17 | Cassidy Sean A | Officer | M-Exempt | A | Common Stock | 15,000 | 16.00 | 240.0K | 173,249 | — | ↗ |
| 2021-12-16 | Ratcliffe Liam | Director | S-Sale | D | Common Stock | 37,206 | 68.97 | 2.57M | 185,686 | — | ↗ |
| 2021-12-15 | Ratcliffe Liam | Director | S-Sale | D | Common Stock | 67,549 | 66.50 | 4.49M | 277,086 | — | ↗ |
| 2021-12-14 | Ratcliffe Liam | Director | S-Sale | D | Common Stock | 36,308 | 65.38 | 2.37M | 385,627 | — | ↗ |
| 2021-11-15 | Taylor Ian | Officer | M-Exempt | D | Stock Option (right to buy) | 7,794 | 19.36 | 150.9K | 57,633 | — | ↗ |
| 2021-11-15 | Ratcliffe Liam | Director | S-Sale | D | Common Stock | 3,532 | 83.90 | 296.3K | 541,391 | — | ↗ |
| 2021-11-12 | Ratcliffe Liam | Director | S-Sale | D | Common Stock | 9,660 | 84.31 | 814.5K | 575,435 | — | ↗ |
| 2021-11-11 | Ratcliffe Liam | Director | S-Sale | D | Common Stock | 5,582 | 87.71 | 489.6K | 656,761 | — | ↗ |
| 2021-11-10 | Ratcliffe Liam | Director | S-Sale | D | Common Stock | 199 | 86.59 | 17.2K | 662,343 | — | ↗ |
| 2021-11-09 | Ratcliffe Liam | Director | S-Sale | D | Common Stock | 27,297 | 91.85 | 2.51M | 676,281 | — | ↗ |
| 2021-11-08 | Ratcliffe Liam | Director | S-Sale | D | Common Stock | 54,568 | 94.93 | 5.18M | 735,195 | — | ↗ |
| 2021-11-05 | Ratcliffe Liam | Director | S-Sale | D | Common Stock | 2,747 | 89.86 | 246.9K | 789,763 | — | ↗ |
| 2021-11-01 | Houston John G | Director / Officer | M-Exempt | A | Common Stock | 40,000 | 16.00 | 640.0K | 872,333 | — | ↗ |
| 2021-09-07 | SHANNON TIMOTHY M | Director | S-Sale | D | Common Stock | 2,030 | 90.75 | 184.2K | 1,653,128 | — | ↗ |
| 2021-09-03 | SHANNON TIMOTHY M | Director | S-Sale | D | Common Stock | 2,319 | 86.39 | 200.3K | 1,689,539 | — | ↗ |
| 2021-09-02 | SHANNON TIMOTHY M | Director | S-Sale | D | Common Stock | 28,449 | 85.42 | 2.43M | 1,745,242 | — | ↗ |
| 2021-09-02 | Houston John G | Director / Officer | M-Exempt | A | Common Stock | 2,462 | 16.00 | 39.4K | 832,333 | — | ↗ |
| 2021-09-01 | SHANNON TIMOTHY M | Director | S-Sale | D | Common Stock | 18,821 | 85.67 | 1.61M | 1,834,307 | — | ↗ |
| 2021-08-31 | SHANNON TIMOTHY M | Director | S-Sale | D | Common Stock | 47,166 | 85.39 | 4.03M | 1,865,317 | — | ↗ |
| 2021-08-30 | SHANNON TIMOTHY M | Director | S-Sale | D | Common Stock | 25,469 | 86.40 | 2.20M | 1,921,245 | — | ↗ |
| 2021-08-27 | SHANNON TIMOTHY M | Director | S-Sale | D | Common Stock | 2,371 | 86.06 | 204.0K | 1,971,321 | — | ↗ |
| 2021-08-26 | SHANNON TIMOTHY M | Director | S-Sale | D | Common Stock | 11,712 | 85.12 | 997.0K | 2,016,347 | — | ↗ |
| 2021-08-26 | Margus Bradley Albert | Director | S-Sale | D | Common Stock | 9,940 | 85.03 | 845.2K | 2,000 | — | ↗ |
| 2021-08-25 | SHANNON TIMOTHY M | Director | S-Sale | D | Common Stock | 14,267 | 85.03 | 1.21M | 2,028,059 | — | ↗ |
| 2021-08-25 | Margus Bradley Albert | Director | S-Sale | D | Common Stock | 20,000 | 85.00 | 1.70M | 11,940 | — | ↗ |
| 2021-08-24 | SHANNON TIMOTHY M | Director | S-Sale | D | Common Stock | 4,568 | 86.95 | 397.2K | 2,046,961 | — | ↗ |
| 2021-08-23 | SHANNON TIMOTHY M | Director | S-Sale | D | Common Stock | 1,599 | 88.01 | 140.7K | 2,051,529 | — | ↗ |
| 2021-08-16 | Taylor Ian | Officer | S-Sale | D | Common Stock | 10,462 | 87.67 | 917.2K | 78,946 | — | ↗ |
| 2021-08-13 | Margus Bradley Albert | Director | S-Sale | D | Common Stock | 5,828 | 90.03 | 524.7K | 31,940 | — | ↗ |
| 2021-08-12 | Peck Ronald | Officer | M-Exempt | D | Restricted Stock Units | 4,011 | 0.00 | — | 8,020 | — | ↗ |
| 2021-08-11 | Margus Bradley Albert | Director | S-Sale | D | Common Stock | 5,000 | 90.03 | 450.2K | 37,768 | — | ↗ |
| 2021-08-02 | Houston John G | Director / Officer | S-Sale | D | Common Stock | 7,600 | 98.86 | 751.3K | 833,830 | — | ↗ |
| 2021-07-28 | Cassidy Sean A | Officer | M-Exempt | A | Common Stock | 17,242 | 16.00 | 275.9K | 175,491 | — | ↗ |
| 2021-06-30 | Peck Ronald | Officer | M-Exempt | D | Stock Option (right to buy) | 20,000 | 47.38 | 947.6K | 55,000 | — | ↗ |
| 2021-06-10 | Houston John G | Director / Officer | S-Sale | D | Common Stock | 11,784 | 81.75 | 963.4K | 842,130 | — | ↗ |
| 2021-06-09 | Houston John G | Director / Officer | M-Exempt | A | Common Stock | 700 | 16.00 | 11.2K | 828,343 | — | ↗ |
| 2021-06-08 | Smaldone Alsup Laurie | Director | A-Award | A | Stock Option (right to buy) | 7,511 | 78.53 | 589.8K | 7,511 | — | ↗ |
| 2021-06-08 | SHANNON TIMOTHY M | Director | A-Award | A | Stock Option (right to buy) | 7,511 | 78.53 | 589.8K | 7,511 | — | ↗ |
| 2021-06-08 | Ratcliffe Liam | Director | A-Award | A | Stock Option (right to buy) | 7,511 | 78.53 | 589.8K | 7,511 | — | ↗ |
| 2021-06-08 | Norwalk Leslie V | Director | A-Award | A | Stock Option (right to buy) | 7,511 | 78.53 | 589.8K | 7,511 | — | ↗ |
| 2021-06-08 | Morrison Briggs | Director | A-Award | A | Stock Option (right to buy) | 7,511 | 78.53 | 589.8K | 7,511 | — | ↗ |
| 2021-06-08 | Margus Bradley Albert | Director | A-Award | A | Stock Option (right to buy) | 7,511 | 78.53 | 589.8K | 7,511 | — | ↗ |
| 2021-06-08 | Kennedy Edward Moore Jr. | Director | A-Award | A | Stock Option (right to buy) | 7,511 | 78.53 | 589.8K | 7,511 | — | ↗ |
| 2021-06-08 | DIXON WENDY L | Director | A-Award | A | Stock Option (right to buy) | 7,511 | 78.53 | 589.8K | 7,511 | — | ↗ |
| 2021-06-08 | Bain Linda | Director | A-Award | A | Stock Option (right to buy) | 7,511 | 78.53 | 589.8K | 7,511 | — | ↗ |
| 2021-04-06 | Kennedy Edward Moore Jr. | Director | — | I | Common Stock | 0 | 0.00 | — | 29,333 | — | ↗ |
| 2021-04-05 | Taylor Ian | Officer | M-Exempt | A | Common Stock | 25,000 | 16.00 | 400.0K | 103,645 | — | ↗ |
| 2021-03-02 | Taylor Ian | Officer | M-Exempt | D | Restricted Stock Units | 2,685 | 0.00 | — | 5,371 | — | ↗ |
| 2021-03-02 | Houston John G | Director / Officer | M-Exempt | D | Restricted Stock Units | 17,510 | 0.00 | — | 35,021 | — | ↗ |
| 2021-03-02 | Cassidy Sean A | Officer | M-Exempt | A | Common Stock | 4,792 | 0.00 | — | 160,470 | — | ↗ |
| 2021-02-26 | Taylor Ian | Officer | A-Award | A | Stock Option (right to buy) | 68,000 | 78.30 | 5.32M | 0 | — | ↗ |
| 2021-02-26 | Peck Ronald | Officer | A-Award | A | Stock Option (right to buy) | 68,000 | 78.30 | 5.32M | 0 | — | ↗ |
| 2021-02-26 | Houston John G | Director / Officer | A-Award | A | Stock Option (right to buy) | 219,500 | 78.30 | 17.19M | 0 | — | ↗ |
| 2021-02-26 | Cassidy Sean A | Officer | A-Award | A | Stock Option (right to buy) | 68,000 | 78.30 | 5.32M | 0 | — | ↗ |
| 2021-02-19 | Taylor Ian | Officer | M-Exempt | D | Stock Option (right to buy) | 704 | 16.00 | 11.3K | 596 | — | ↗ |
| 2021-02-17 | Cassidy Sean A | Officer | M-Exempt | A | Common Stock | 569 | 16.00 | 9.1K | 155,678 | — | ↗ |
| 2021-02-16 | Peck Ronald | Officer | S-Sale | D | Common Stock | 20,000 | 77.35 | 1.55M | 2,754 | — | ↗ |
| 2021-02-16 | Houston John G | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 1,560 | 16.00 | 25.0K | 87,320 | — | ↗ |
| 2021-02-16 | Cassidy Sean A | Officer | M-Exempt | A | Common Stock | 6,815 | 16.00 | 109.0K | 161,599 | — | ↗ |
| 2020-12-31 | Houston John G | Director / Officer | A-Award | A | Common Stock | 310 | 29.02 | 9.0K | 818,248 | — | ↗ |
| 2020-12-18 | Ratcliffe Liam | Director | P-Purchase | A | Common Stock | 142,857 | 70.00 | 10.00M | 822,857 | — | ↗ |
| 2020-11-09 | Kennedy Edward Moore Jr. | Director | P-Purchase | A | Common Stock | 8,333 | 23.99 | 199.9K | 42,718 | — | ↗ |
| 2020-11-09 | Cassidy Sean A | Officer | M-Exempt | D | Stock Option (right to buy) | 2,356 | 16.00 | 37.7K | 22,696 | — | ↗ |
| 2020-10-14 | Canaan IX L.P. | 10% Owner | J-Other | D | Common Stock | 400,000 | 0.00 | — | 3,589,554 | — | ↗ |
| 2020-08-14 | Peck Ronald | Officer | S-Sale | D | Common Stock | 1,256 | 27.46 | 34.5K | 2,754 | — | ↗ |
| 2020-07-20 | Canaan IX L.P. | 10% Owner | J-Other | D | Common Stock | 500,000 | 0.00 | — | 3,989,554 | — | ↗ |
| 2020-06-30 | Houston John G | Director / Officer | A-Award | A | Common Stock | 315 | 28.50 | 9.0K | 817,938 | — | ↗ |
| 2020-06-29 | DIXON WENDY L | Director | A-Award | A | Stock Option (right to buy) | 24,000 | 31.95 | 766.8K | 24,000 | — | ↗ |
| 2020-06-17 | SHANNON TIMOTHY M | Director | P-Purchase | A | Common Stock | 2,000 | 30.26 | 60.5K | 79,546 | — | ↗ |
| 2020-06-10 | Bain Linda | Director | A-Award | A | Stock Option (right to buy) | 24,000 | 33.43 | 802.3K | 24,000 | — | ↗ |
| 2020-06-03 | Smaldone Alsup Laurie | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 33.57 | 402.8K | 12,000 | — | ↗ |
| 2020-06-03 | SHANNON TIMOTHY M | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 33.57 | 402.8K | 12,000 | — | ↗ |
| 2020-06-03 | Ratcliffe Liam | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 33.57 | 402.8K | 12,000 | — | ↗ |
| 2020-06-03 | Norwalk Leslie V | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 33.57 | 402.8K | 12,000 | — | ↗ |
| 2020-06-03 | Morrison Briggs | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 33.57 | 402.8K | 12,000 | — | ↗ |
| 2020-06-03 | Margus Bradley Albert | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 33.57 | 402.8K | 12,000 | — | ↗ |
| 2020-06-03 | Loven Jakob | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 33.57 | 402.8K | 12,000 | — | ↗ |
| 2020-06-03 | Kennedy Edward Moore Jr. | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 33.57 | 402.8K | 12,000 | — | ↗ |
| 2020-06-02 | SHANNON TIMOTHY M | Director | P-Purchase | A | Common Stock | 3,000 | 32.30 | 96.9K | 77,546 | — | ↗ |
| 2020-05-26 | SHANNON TIMOTHY M | Director | M-Exempt | D | Stock Option (right to buy) | 12,923 | 22.06 | 285.1K | 0 | — | ↗ |
| 2020-05-26 | Ratcliffe Liam | Director | M-Exempt | D | Stock Option (right to buy) | 6,500 | 22.06 | 143.4K | 6,423 | — | ↗ |
| 2020-05-13 | Cassidy Sean A | Officer | M-Exempt | D | Stock Option (right to buy) | 1,139 | 16.00 | 18.2K | 25,052 | — | ↗ |
| 2020-05-12 | Cassidy Sean A | Officer | S-Sale | D | Common Stock | 10,000 | 60.00 | 600.0K | 150,422 | — | ↗ |
| 2020-03-24 | Morrison Briggs | Director | P-Purchase | A | Common Stock | 2,500 | 38.18 | 95.5K | 29,520 | — | ↗ |
| 2020-03-23 | Houston John G | Director / Officer | M-Exempt | A | Common Stock | 6,250 | 16.00 | 100.0K | 816,200 | — | ↗ |
| 2020-03-23 | Cassidy Sean A | Officer | M-Exempt | A | Common Stock | 8,030 | 16.00 | 128.5K | 160,422 | — | ↗ |
| 2020-03-20 | SHANNON TIMOTHY M | Director | P-Purchase | A | Common Stock | 2,500 | 40.00 | 100.0K | 61,623 | — | ↗ |
| 2020-03-19 | Taylor Ian | Officer | M-Exempt | D | Restricted Stock Units | 2,686 | 0.00 | — | 8,056 | — | ↗ |
| 2020-03-19 | Houston John G | Director / Officer | S-Sale | D | Common Stock | 5,405 | 37.61 | 203.3K | 809,950 | — | ↗ |
| 2020-03-19 | Cassidy Sean A | Officer | M-Exempt | D | Restricted Stock Units | 4,791 | 0.00 | — | 14,374 | — | ↗ |
| 2020-03-18 | Margus Bradley Albert | Director | S-Sale | D | Common Stock | 40,000 | 37.46 | 1.50M | 59,463 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-187.2K
Shares Outstanding
63.96M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | John Houston, Ph.D. Former President and Chief Executive Officer | 706.2K | — | 2.69M | 2.67M | 457.0K | 14.0K | 6.53M | 81.98% | ↗ |
| 2 | 2025 | Noah Berkowitz, M.D., Ph.D. Chief Medical Officer | 552.4K | — | 1.37M | 1.39M | 268.5K | 14.0K | 3.59M | 76.77% | ↗ |
| 3 | 2025 | Andrew Saik Chief Financial Officer and Treasurer | 542.1K | — | 1.26M | 1.28M | 263.5K | 14.0K | 3.36M | 75.63% | ↗ |
| 4 | 2025 | Angela Cacace, Ph.D. Chief Scientific Officer | 500.8K | — | 1.26M | 1.28M | 243.4K | 14.0K | 3.30M | 77.03% | ↗ |
| 5 | 2025 | Ian Taylor, Ph.D. Former President of Research and Development | 152.6K | — | 364.3K | 362.5K | — | 24.0K | 903.4K | 80.45% | ↗ |
| 6 | 2024 | President and Chief Executive Officer | 684.0K | — | 5.85M | 5.77M | 426.8K | 13.8K | 12.75M | 91.18% | ↗ |
| 7 | 2024 | John Houston, Ph.D. Former President and Chief Executive Officer | 684.0K | — | 5.85M | 5.77M | 426.8K | 13.8K | 12.75M | 91.18% | ↗ |
| 8 | 2024 | Noah Berkowitz, M.D., Ph.D. Chief Medical Officer | 421.8K | — | 2.70M | 2.65M | 197.5K | 13.8K | 5.98M | 89.42% | ↗ |
| 9 | 2024 | Chief Medical Officer | 421.8K | — | 2.70M | 2.65M | 197.5K | 13.8K | 5.98M | 89.42% | ↗ |
| 10 | 2024 | President of Research and Development | 367.9K | — | 1.84M | 1.82M | 172.2K | 13.8K | 4.22M | 86.87% | ↗ |
| 11 | 2024 | Ian Taylor, Ph.D. Former President of Research and Development | 367.9K | — | 1.84M | 1.82M | 172.2K | 13.8K | 4.22M | 86.87% | ↗ |
| 12 | 2024 | Former interim Chief Financial Officer | 475.0K | — | 1.55M | 1.52M | 222.3K | 13.8K | 3.78M | 81.17% | ↗ |
| 13 | 2024 | Chief Financial Officer and Treasurer | 272.6K | — | 1.53M | 1.53M | 127.6K | 4.8K | 3.47M | 88.31% | ↗ |
| 14 | 2024 | Andrew Saik Chief Financial Officer and Treasurer | 272.6K | — | 1.53M | 1.53M | 127.6K | 4.8K | 3.47M | 88.31% | ↗ |
| 15 | 2024 | Angela Cacace, Ph.D. Chief Scientific Officer | 464.8K | — | 1.14M | 1.13M | 217.6K | 13.8K | 2.97M | 76.58% | ↗ |
| 16 | 2024 | Chief Scientific Officer | 464.8K | — | 1.14M | 1.13M | 217.6K | 13.8K | 2.97M | 76.58% | ↗ |
| 17 | 2024 | Former Chief Financial Officer and Treasurer | 92.3K | — | — | — | — | 13.6K | 105.9K | 0.00% | ↗ |
| 18 | 2023 | John Houston, Ph.D. Former President and Chief Executive Officer | 657.7K | — | 2.13M | 4.35M | 473.6K | 13.2K | 7.63M | 84.99% | ↗ |
| 19 | 2023 | John Houston, Ph.D. President and Chief Executive Officer | 657.7K | — | 2.13M | 4.35M | 473.6K | 13.2K | 7.63M | 84.99% | ↗ |
| 20 | 2023 | Ronald Peck, M.D. Former Chief Medical Officer | 473.4K | — | 657.3K | 1.34M | 255.7K | 13.2K | 2.74M | 72.94% | ↗ |
| 21 | 2023 | President of Research and Development | 466.9K | — | 657.3K | 1.34M | 252.2K | 13.2K | 2.73M | 73.21% | ↗ |
| 22 | 2023 | Ian Taylor, Ph.D. Former President of Research and Development | 466.9K | — | 657.3K | 1.34M | 252.2K | 13.2K | 2.73M | 73.21% | ↗ |
| 23 | 2023 | Ian Taylor, Ph.D. Chief Scientific Officer | 466.9K | — | 657.3K | 1.34M | 252.2K | 13.2K | 2.73M | 73.21% | ↗ |
| 24 | 2023 | Sean Cassidy Former Chief Financial Officer | 460.6K | — | 657.3K | 1.34M | 248.8K | 13.2K | 2.72M | 73.46% | ↗ |
| 25 | 2023 | Former Chief Financial Officer and Treasurer | 460.6K | — | 657.3K | 1.34M | 248.8K | 13.2K | 2.72M | 73.46% | ↗ |
| 26 | 2022 | John Houston, Ph.D. President and Chief Executive Officer | 632.4K | — | — | 8.47M | 433.8K | 12.2K | 9.55M | 88.70% | ↗ |
| 27 | 2022 | Ronald Peck, M.D. Former Chief Medical Officer | 455.2K | — | — | 2.83M | 234.2K | 12.2K | 3.53M | 80.13% | ↗ |
| 28 | 2022 | Ronald Peck, M.D. Chief Medical Officer | 455.2K | — | — | 2.83M | 234.2K | 12.2K | 3.53M | 80.13% | ↗ |
| 29 | 2022 | Ian Taylor, Ph.D. Chief Scientific Officer | 448.9K | — | — | 2.83M | 230.9K | 12.2K | 3.52M | 80.35% | ↗ |
| 30 | 2022 | Sean Cassidy Former Chief Financial Officer | 442.9K | — | — | 2.83M | 227.9K | 12.2K | 3.51M | 80.55% | ↗ |
| 31 | 2022 | Sean Cassidy Chief Financial Officer | 442.9K | — | — | 2.83M | 227.9K | 12.2K | 3.51M | 80.55% | ↗ |
| 32 | 2021 | John Houston, Ph.D. President and Chief Executive Officer | 584.1K | — | — | 11.53M | 473.1K | 11.6K | 12.60M | 91.52% | ↗ |
| 33 | 2021 | Ronald Peck, M.D. Former Chief Medical Officer | 435.6K | — | — | 3.57M | 264.7K | 11.6K | 4.28M | 83.38% | ↗ |
| 34 | 2021 | Ronald Peck, M.D. Chief Medical Officer | 435.6K | — | — | 3.57M | 264.7K | 11.6K | 4.28M | 83.38% | ↗ |
| 35 | 2021 | Ian Taylor, Ph.D. Chief Scientific Officer | 420.0K | — | — | 3.57M | 255.2K | 11.6K | 4.26M | 83.88% | ↗ |
| 36 | 2021 | Sean Cassidy Former Chief Financial Officer | 408.1K | — | — | 3.57M | 248.0K | 11.6K | 4.24M | 84.25% | ↗ |
| 37 | 2021 | Sean Cassidy Chief Financial Officer | 408.1K | — | — | 3.57M | 248.0K | 11.6K | 4.24M | 84.25% | ↗ |
| 38 | 2020 | John Houston, Ph.D. President and Chief Executive Officer | 564.3K | — | — | 6.99M | 454.3K | 11.4K | 8.02M | 87.16% | ↗ |
| 39 | 2020 | Ronal Peck, M.D., Chief Medical Officer | 418.0K | — | — | 2.23M | 269.2K | — | 2.92M | 76.45% | ↗ |
| 40 | 2020 | Ronald Peck, M.D. Chief Medical Officer | 418.0K | — | — | 2.23M | 269.2K | — | 2.92M | 76.45% | ↗ |
| 41 | 2020 | Ian Taylor, Ph.D. Chief Scientific Officer | 400.0K | — | — | 2.23M | 257.7K | 11.4K | 2.90M | 76.93% | ↗ |
| 42 | 2020 | Ian Taylor, Ph.D., Chief Scientific Officer | 400.0K | — | — | 2.23M | 257.7K | — | 2.89M | 77.23% | ↗ |
| 43 | 2020 | Sean Cassidy Chief Financial Officer | 375.0K | — | — | 2.23M | 242.0K | 11.4K | 2.86M | 78.02% | ↗ |
| 44 | 2020 | Sean Cassidy, Chief Financial Officer | 375.0K | — | — | 2.23M | 242.0K | — | 2.85M | 78.34% | ↗ |
| 45 | 2019 | John Houston, Ph.D. President and Chief Executive Officer | 527.5K | — | 1.36M | 3.18M | 422.0K | 11.2K | 5.50M | 82.52% | ↗ |
| 46 | 2019 | Sean Cassidy Chief Financial Officer | 336.5K | — | 371.0K | — | 215.4K | 11.2K | 2.03M | 18.28% | ↗ |
| 47 | 2019 | Sean Cassidy, Chief Financial Officer | 336.5K | — | 371.0K | 1.10M | 215.4K | — | 2.02M | 72.66% | ↗ |
| 48 | 2019 | Ronald Peck, M.D. Chief Medical Officer | 174.3K | 3.0K | 426.4K | 1.21M | 100.3K | — | 1.92M | 85.52% | ↗ |
| 49 | 2019 | Ronald Peck, M.D. Chief Medical Officer | 174.3K | 3.0K | 426.4K | — | 100.3K | — | 1.92M | 22.24% | ↗ |
| 50 | 2019 | Ronal Peck, M.D., Chief Medical Officer | 174.3K | 3.0K | 426.4K | 1.21M | 100.3K | — | 1.92M | 85.52% | ↗ |
| 51 | 2019 | Ian Taylor, Ph.D. Chief Scientific Officer | 315.0K | — | 208.0K | — | 193.8K | 11.2K | 1.55M | 13.46% | ↗ |
| 52 | 2019 | Ian Taylor, Ph.D., Chief Scientific Officer | 315.0K | — | 208.0K | 817.2K | 193.8K | — | 1.53M | 66.83% | ↗ |
| 53 | 2018 | John Houston, Ph.D. President and Chief Executive Officer | 427.8K | — | 942.4K | 4.63M | 278.1K | — | 6.28M | 88.76% | ↗ |
| 54 | 2018 | Sean Cassidy Chief Financial Officer | 265.8K | — | 799.5K | 1.60M | 138.2K | — | 2.80M | 85.58% | ↗ |
| 55 | 2018 | Sean Cassidy, Chief Financial Officer | 265.8K | — | 799.5K | — | 138.2K | — | 2.80M | 28.54% | ↗ |
| 56 | 2018 | Ian Taylor, Ph.D Chief Scientific Officer | 286.8K | — | 562.6K | 998.2K | 137.8K | — | 1.99M | 78.62% | ↗ |
| 57 | 2018 | Ian Taylor, Ph.D., Chief Scientific Officer | 286.7K | — | 562.6K | — | 137.8K | — | 1.99M | 28.34% | ↗ |
| 58 | 2018 | Ronal Peck, M.D., Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 59 | 2017 | John Houston, Ph.D. President and Chief Executive Officer | 370.8K | — | 373.7K | — | 160.0K | 50.0K | 954.4K | 39.15% | ↗ |
| 60 | 2017 | Sean Cassidy Chief Financial Officer | 255.5K | — | — | — | 91.6K | — | 347.1K | 0.00% | ↗ |
| 61 | 2017 | Ian Taylor, Ph.D Chief Scientific Officer | 271.2K | — | — | — | 64.3K | — | 335.5K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Noah Berkowitz | Chief Medical Officer | 834.9K | — |
| Andrew Saik | Chief Financial Officer & Treasurer | 819.6K | male |
| Angela Cacace | Chief Scientific Officer | 758.2K | female |
| Randy Teel | CEO, President & Director | 711.1K | — |
| Kelly Page | Senior Vice President & Global Head of Oncology Strategy and Program Leadership | — | female |
| Lisa Sinclair | Senior Vice President of Corporate Operations | — | female |
| Paul McInulty | Senior Vice President of Regulatory Affairs | — | male |
| Alexander A. Santini | Chief Commercial Officer | — | male |
| Steve Weiss | Senior Vice President & Chief Human Resources Officer | — | male |
| David Loomis | Vice President & Chief Accounting Officer | — | male |
| Jared Freedberg | General Counsel & Corporate Secretary | — | male |
| Jeff Boyle | Vice President of Investor Relations | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ARVN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
